← Back to Search

Stereotactic Body Radiation Therapy for Liver Cancer

Phase 2

Waitlist Available

Led By Nima Nabavizadeh

Research Sponsored by OHSU Knight Cancer Institute

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 4 years

Awards & highlights

Summary

This trial is testing whether Y-90 segmentectomy or stereotactic body radiation therapy is better in treating inoperable liver cancer.

Eligible Conditions

Liver Cancer
Hepatocellular Carcinoma

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 4 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 4 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 4 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Feasibility of enrollment (enrollment rate)

Secondary outcome measures

Change in patient reported quality of life

Rate of non-classic radiation induced liver disease

Side effects data

From 2022 Phase 2 trial • 29 Patients • NCT02045446

87%

Fatigue

53%

Nausea

33%

Cough

27%

Dyspnea

27%

Depression

27%

Anemia

27%

Platelet count decreased

27%

Fall

27%

Lymphocyte count decreased

27%

Pain

20%

Diarrhea

20%

Chills

20%

Edema limbs

20%

Neutropenia

20%

Dizziness

20%

Chest pain

13%

Dysesthesia

13%

Skin infection

13%

Vomiting

13%

Back pain

13%

Edema

13%

Insomnia

13%

Tinnitus

13%

Constipation

13%

Delirium

13%

Dysgeusia

13%

Myalgia

13%

Rash

13%

Weakness (limb)

13%

Weight loss

Oral lesions

Hypoxic respiratory failure

Hypernatremia

Proteinuria

Seizures

Headaches

Death NOS

Encephalopathy

Gait disturbance

Cognitive disturbance

Fever

Sneezing

Tremor

Urinary frequency

Amnesia

Lung infection

Acute kidney injury

Hypertension

Allergy (seasonal)

Bruising

Febrile Neutropenia

Anxiety

Anorexia

Creatinine increased

Dysphagia

Hypokalemia

Hypomagnesemia

Erythema multitforme

Headache

Hearing impaired

Hearing loss

Low white blood count

Lymphocytopenia

Muscle weakness

Nasal congestion

Neutrophil count decreased

Parathesia (tingling)

Photophobia

Pleural effusion

Sleep apnea

Urinary urgency

Weakness (facial)

Hypoxia

Shingles

100%

80%

60%

40%

20%

Study treatment Arm

Maintenance Chemotherapy

Stereotactic Body Radiation Therapy

Trial Design

2Treatment groups

Experimental Treatment

Group I: Arm II (Y-90 radioembolization)Experimental Treatment3 Interventions

Patients receive Y-90 radioembolization via injection on day 1.

Group II: Arm I (SBRT)Experimental Treatment3 Interventions

Patients undergo SBRT every other day for a total of 5 days over 2 weeks.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Stereotactic Body Radiation Therapy

2012

Completed Phase 2

~790

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

American Society of Clinical OncologyOTHER

37 Previous Clinical Trials

148,149 Total Patients Enrolled

1 Trials studying Liver Cancer

33 Patients Enrolled for Liver Cancer

Medical Research Foundation, OregonOTHER

13 Previous Clinical Trials

1,116 Total Patients Enrolled

Oregon Health and Science UniversityOTHER

994 Previous Clinical Trials

7,386,948 Total Patients Enrolled

1 Trials studying Liver Cancer

339 Patients Enrolled for Liver Cancer

~0 spots leftby Jan 2026

Unbiased ResultsWe believe in providing patients with all the options.

Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.

Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.